Praesidia Biotherapeutics

Crossing the blood-brain barrier is critical to increasing therapeutic windows for viable therapies. Organ- and cell-specific delivery is exactly what Praesidias platform does, unlocking the best possible standard of care

Biotherapeutics,drug discovery,blood brain barrier penetration,linker enzyme substrate system (less),prodrug,targeted therapy,neuro-oncology,oncology,central nervous system (cns),neurodegenerative diseases,blood brain barrier (bbb),computational modeling,dose-limiting toxicity,ncreasing maximum tolerable dose (mtd),maximizing therapeutic index,medicine,chemistry,manufacturing and controls (cmc),oral formulation,biologics,and biotechnology

Praesidia biotherapeutics operates in the Biotechnology research industry.

Praesidia biotherapeutics's revenue is 11m - 100m

Praesidia biotherapeutics has 11 - 50 employees.